CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM) Quality of Life after Everolimus-Eluting Stents or Bypass Surgery for Treatment of Left Main Disease Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Echocardiographic Screening for Pulmonary Hypertension in Congenital Heart Disease: JACC Review Topic of the Week Intravascular Ultrasound Parameters Associated With Stent Thrombosis After Drug-Eluting Stent Deployment The impact of intravascular ultrasound guidance during drug eluting stent implantation on angiographic outcomes Successful bailout stenting strategy against lethal coronary dissection involving left main bifurcation Contribution of stent underexpansion to recurrence after sirolimus-eluting stent implantation for in-stent restenosis Histopathologic validation of the intravascular ultrasound diagnosis of calcified coronary artery nodules

Original Research2021 Jan 3.

JOURNAL:Clin Res Cardiol. Article Link

Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis

G Bugani, M Pagnesi, D Tchetchè et al. Keywords: TAVR; balloon-expandable valve; bicuspid; high residual gradient; self-expandable valve;

ABSTRACT

OBJECTIVES - To define the incidence of high residual gradient (HRG) after transcatheter aortic valve replacement (TAVR) in BAVs and their impact on short term outcome and 1-year mortality.


BACKGROUND - Transcatheter heart valves (THVs) offer good performance in tricuspid aortic valves with low rate of HRG. However, data regarding their performance in bicuspid aortic valves (BAV) are still lacking.


METHODS - The BEAT (Balloon vs Self-Expandable valve for the treatment of bicuspid Aortic valve sTenosis) registry included 353 consecutive patients who underwent TAVR (Evolut R/PRO or Sapien 3 valves) in BAV between June 2013 and October 2018. The primary endpoint was device unsuccess with post-procedural HRG (mean gradient20 mmHg). The secondary endpoint was to identify the predictors of HRG following the procedure.


RESULTS - Twenty patients (5.6%) showed HRG after TAVR. Patients with HRG presented higher body mass index (BMI) (30.7 ± 9.3 vs. 25.9 ± 4.8; p < 0.0001) and higher baseline aortic mean gradients (57.6 ± 13.4 mmHg vs. 47.7 ± 16.6, p = 0.013) and more often presented with BAV of Sievers type 0 than patients without HRG. At multivariate analysis, BMI [odds ratio (OR) 1.12; 95% confidence interval (CI) 1.051.20, p = 0.001] and BAV type 0 (OR 11.31, 95% CI 3.4537.06, p < 0.0001) were confirmed as independent predictors of high gradient.


CONCLUSION - HRG following TAVR in BAVs is not negligible and is higher among patients with high BMI and with BAV 0 anatomy.